Bradykinin is known to effect a vasodilatation of feline cerebral arteries in situ and of both human and feline pial arteries in vitro, In order to demonstrate whether kininase II (localized within the vessel wall or in the sur rounding tissue or fluid) influences the response to bra dykinin, two different inhibitors of this bradykinin deg radation enzyme were tested. Perivascular microappli cation of potentiator C (10-1°_10 -4 M) or captopril (10 -10_ 10-3 M) did not, by itself, change the diameter of feline pial arteries (87-305 J,Lm) in situ. In a similar investigation, the dilating action of bradykinin (10-clO-' M) was not modified by the simultaneous application of potentiator C or captopril (10-5 M). Furthermore, the relaxing effect of bradykinin (1O-1LlO-4 M) on isolated feline middle ce rebral arteries (preconstricted with 5-hydroxytryptamine or prostaglandin F2.) was not influenced by the presence of captopril (10-7 M). In contrast, when studied on iso lated extracranial vessel segments (feline sublingual ar-
We have shown previously that the in vitro effect of bradykinin on human and feline cerebral arteries and arterioles is vasodilation; a similar response was observed on feline pial arteries in situ (Wahl et aI., 1983) . One factor involved in the determination of the intensity and duration of the effects induced by endogenous and exogenous bradykinin is its enzy matic degradation. Kininase-like activity has been found in blood, cerebral microvessels, and the brain. Gimbrone et al. (1979) detected kininase II in iso lated bovine microvessels, and Kariya et al. (1981) have shown in the rat brain that a part of the total cerebral kininase activity is due to kininase II. AI-tery), bradykinin caused a concentration-dependent con striction of the artery. This constriction was completely reversed to dilatation in the presence of captopril (10-7 M). Moreover, the characteristic effect of kininase II in hibition was demonstrated in the isolated guinea pig ileum preparation. In this instance, bradykinin induced a con centration-dependent contraction that was enhanced by potentiator C or captopril. We conclude, therefore, that bradykinin exerts variable responses on vascular smooth muscle, depending on the species used, the muscle lo cation and experimental conditions. Finally, the in situ and in vitro findings for pial and middle cerebral arteries demonstrate that kininase II does not modify the dilating effect of bradykinin under our experimental conditions. though kininase II is mainly a membrane-bound en zyme, it is also present in body fluids such as blood and seminal plasma, lymph, and urine (Erdos, 1979) . We are not aware of any report that demonstrates kininase II activity in cerebrospinal fluid.
We have attempted to determine if kininase II is present in the perivascular fluid or surrounding tissue of extraparenchymal cerebral pial arteries and, if so, whether it influences the vasomotor effects of bradykinin administered from the parenchymal side. This was tested by microapplication of two different kininase II inhibitors in situ. In addition, the effect of a kininase II inhibitor on the bradykinin-induced dilatation of the middle cerebral artery in vitro was tested in order to elucidate whether kininase II ac tivity is found in the walls of cerebral arteries. Cor responding experiments were performed on the sublingual artery in vitro to characterize differences between intracranial and extracranial arteries.
Two kininase inhibitors were used: potentiator C, an undecapeptide isolated from snake venom (Kato and Suzuki, 1971 ) and the more potent and specific inhibitor captopril (SQ 14225) . This compound, a D-3-mercapto-2-methylpropanoyl-L-proline, has re cently been developed (Cushman et aI., 1979; Cushman and Ondetti, 1980) . To assure the validity of the data obtained on the cerebral and sublingual arteries experiments were performed on the iso lated guinea pig ileum, which is known to contain large amounts of kininase II and is an established bioassay for testing bradykinin-potentiating pep tides or kininase II inhibitors (Rubin et aI., 1978) .
EXPERIMENTAL PROCEDURES

Intra-and extracranial arteries in vitro
Preparation and recording of effects. Experiments were performed on blood vessels taken from cats of both sexes weighing 2.0-2.5 kg. The cats were exsanguinated and decapitated under 5% halothane anaesthesia; the brain was removed, and the middle cerebral and sublingual ar . teries were dissected out immediately and placed in cold Krebs-Ringer buffer solution. Full details of the experi mental conditions have been reported by Young et al. (1981) and Wahl et al. (1983) .
Initially, the effect of bradykinin was tested during the resting state on segments of both middle cerebral and sublingual arteries. In a separate experiment, some ves sels were constricted by the addition of either prosta glandin F2a (PGF2.) (2.5 x 10-6 M) or 5-hydroxytryptamine (5-HT) (3 x 10-7 M) to the bath solutions in order to identify clearly any vasodilating response. Vessels that did not respond to this tonic constriction were discarded. Concentration-response curves were obtained for brady kinin following the cumulative addition of the agonist in concentrations ranging from 10-1 0 to 10-4 M; each vessel was studied only once. Subsequently, calculations were made of the EC 5 0 value (the concentration of agonist pro ducing half-maximal response) and EArn value (the maxi mal response of the vessel).
In some instances, the kininase II inhibitor captopril (10-7 M) was added to the bathing medium 5 min before the administration of bradykinin and was present throughout the duration of the experiment.
Statistical analysis. An analysis of variance was per formed to assure a compatibility between the two groups. If the groups were considered to be compatible, Student's t test was used to evaluate the significance of difference between mean values, the criterion of which was taken to be p < 0.05. Where this test was inappropriate, the test according to the method of Cochran was applied.
Pial arteries in situ
Preparation and recording of effects. Experiments were performed on 14 cats of both sexes (2.6 -4.5 kg), which were anaesthetized with a-chloralose (40 -50 mg/kg, i.v.) and immobilized with gallamine (15-20 mg/kg·h, i. v.). During artificial ventilation, the following parameters were measured in the arterial blood (mean ± SD): pH, 7.38 ± 0.02; Peo2, 28.5 ± 1.8 mm Hg; POz, 135 ± 10 mm Hg. End-tidal CO2 was 4.3 ± 0.2 (vol %). Surgical procedure, treatment of the cats, micropuncture technique, re- Vol, 3, No, 3, 1983 cording of vascular diameter, and composition and storage of the solutions used for perivascular application were the same as described in detail in a previous paper (Wahl et a!., 1983) .
The experiment protocol was as follows: after re cording the resting diameter of the artery (87-305 f,lm), its reactivity was tested with high-and low-bicarbonate solutions (Wahl et aI., 1970; Kuschinsky et aI., 1972) . Inert mock cerebrospinal fluid, which was used as a sol vent for the drugs, was applied to the artery. This resulted in a dilatation of 0.27 ± 0.65% (mean ± SEM). Following this, in one group of experiments, the effects of two dif ferent kininase II inhibitors-potentiator C or captopril were tested by perivascular injection of ascending or random concentrations (10-1°-10-3 M). In another group of experiments, drugs were injected into the perivascular space of the same artery in the following sequence: first, ascending or single concentrations (10-ClO-5 M) of bra dykinin; then, 10-5 M potentiator C or captopril; and fi n � lIy, 10-5 M potentiator C or captopril simultaneously with concentrations of bradykinin corresponding to those used in the first application (which was without a kininase II inhibitor). The data shown in the figures were obtained after subtraction of the respective solvent effects. In ad dition, the small effect of the kininase II inhibitor was subtracted from the values obtained during the simulta neous application of bradykinin and a kininase II inhib itor.
Isolated guinea pig ileum
Preparation and recording of effects. Experiments were performed on the isolated terminal section of the guinea pig ileum with a bath solution and equipment for the mea surement of isometric contraction identical to those de scribed in a previous paper (Wahl et aI., 1983) . The test solutions had the same ionic composition as the inert mock cerebrospinal fluid used for perivascular microapplica tion, and were treated and stored under identical condi tions. The experimental protocol was as follows. After the recovery period, the solvent alone was tested first. Thereafter, a concentration-response curve for brady kinin (1.6 x 1O-L1.6 x 1O-6M) was obtained. Following this procedure, 1.6 x 10-7 M of potentiator C or captopril was tested. Finally, a kininase II inhibitor was given ei ther simultaneously with or 2 min prior to the adminis tration of bradykinin. That data for bradykinin shown in the figures were obtained after subtraction of the respec tive solvent effects. As mentioned previously, the small effect of either kininase II inhibitor was subtracted from the values obtained during the simultaneous application of bradykinin and a kininase II inhibitor.
Statistical analysis. The statistical analyses of the data obtained for the pial arteries in situ and the isolated guinea pig ileum were made by an analysis of variance and mul tiple comparison, according to the method of Scheffe (1953) . In addition, we used a paired t test with the se quentially rejective Bonferroni procedure to assure the multiple level of significance, according to the method of Holm (1979) . The 99% level was taken as significant.
Materials
The following drugs were used: bradykinin-triacetate (Serva or Sigma), captopril (Squibb), bradykinin poten tiator C (Peninsula), 5-HT creatine sulphate (Sigma), and PGF2• (Amoglandin®, Astra).
RESULTS
Middle cerebral artery in vitro
Concentration-response curves were obtained as bradykinin was applied to each vessel in a cumu lative manner; this procedure was carried out only once on each vessel segment. Bradykinin, in in creasing concentrations (10-1 0 -10-4 M), had no ef fect whatsoever on resting middle cerebral arteries (n = 4) ( Fig. 2, upper panel) .
When the vessels were given an active tonic con striction by PGF2u, bradykinin effected a relaxation of the artery (Fig. 1, upper panel) . EC50 and EArn (mean ± SEM) were calculated to be 4. 1 ± 2.4 x 10-8 M and -63 ± 7%, respectively. EArn is ex- (EArn = -62 ± 13%; EC50 = 0.03 ± 0.02 (.LM), which was not significantly different from that observed in PGF2.-con stricted vessels. Captopril did not influence the overall re sponse to bradykinin (half-filled squares) (EArn = -60 ± 11%; EC50 = 0.03 ± 0.03 (.LM). *, p < 0.05, when compared to bradykinin alone (Student's paired t test).
pressed as a percentage of the PGF2u-induced tone (5.3 ± 1.4 mN).
In a separate investigation, captopril (10-7 M) was added to the bath medium 5 min before administra tion of bradykinin and was present throughout the experiment. Captopril had no effect on the arteries by itself, nor did it modify the EC50 obtained for bradykinin (4.9 ± 2.9 x 10-8 M). Likewise, the EArn remained unchanged (-55 ± 9%) ( Fig. 1, upper  panel) .
For comparison, a similar investigation was per formed in which 5-HT was used to preconstrict the pial arteries (9.1 ± 2.5 mN). The dilating effect of bradykinin (EC5o = 2.9 ± 2.5 x 10-8 M; EArn = -62 ± 13%) was not significantly different from that obtained when PGF2u was employed ( Fig. 1,  lower panel) . Once again, under the stated experi mental conditions, captopril had no effect whatso ever upon the bradykinin-induced vasodilatation of 5-HT-constricted arteries (EC5o = 2.6 ± 3.5 x 10-8 M; EArn = -60 ± 11%) ( Fig. 1, lower panel) .
Sublingual artery in vitro
In contrast to the middle cerebral artery, brady kinin produced a strong vasoconstriction of the sub lingual artery under resting conditions. The EArn was 7.8 ± 1.6 mN, and the EC50 was 2.5 ± 0.3 x 10-5 M (Fig. 2, upper panel) . When the sublingual artery was preconstricted with PGF2u (8.9 ± 3.0 mN), the cumulative addition of bradykinin (10-1 0 -10-5 M) resulted in a vasoconstriction of considerably smaller magnitude (Fig. 2, upper panel) . The EArn and EC50 were 2.2 ± 0.3 mN and 7.6 ± 5.4 x 10-8 M, re spectively.
When captopril was present in the bath medium under these conditions (i.e., PGF2u-constricted ves sels), bradykinin effected a marked vasodilatation on extracranial vessels (Fig. 2, lower panel) . This opposite effect resulted in an EArn of -59 ± 3% and an EC5 0 of 2.4 ± 0.7 x 10-8 M (Fig. 2, lower  panel) . We observed in two resting vessel segments (not shown) that, in the presence of captopril, the vasoconstriction induced by bradykinin was com pletely abolished. However, we should point out that no effect of vasodilatation would have been possible, due to the lack of a pharmacologically in duced tone.
Pial arteries in situ Figure 3 shows the average concentration-re sponse curves of potentiator C and captopril, which were applied into the perivascular space of single pial arteries. Potentiator C induced minimal vas cular reactions varying between 1.02% constriction and 0.97% dilatation over the concentration range 
60
.li used to preconstrict these vessels (filled triangles) (EAm = 2.2 ± 0.3 mN; EC5D = 0.08 ± 0.05 )LM). When constructing this curve, we took the preconstriction (8.9 ± 3.0 mN) induced by PGF2u as zero. Lower panel: Effect of captopril (0.1 )LM) on the response to bradykinin of extracranial arteries (half filled triangles) (EAm = 59 ± 3%; ECso = 0.02 ± 0.01 )LM).
All values are expressed as means ± SEM.
of 10-1 0 -10-4 M. Minimal dilatations varying be tween 0.53% and 3.1 % were measured during the application of captopril (10 -1 0 -10 -3 M). Statistical analysis revealed that the reactions produced by po- tentiator C or captopril were not different from the reactions caused by the solvent itself, which were taken as the control values. At a concentration of 10-5 M, potentiator C and captopril elicited dilata tions of 0.21% and 1.07%, respectively. To test whether kininase II participates in the deg radation of perivascularly applied bradykinin, we examined the effects of potentiator C and captopril on bradykinin-induced dilatations. The effects due to bradykinin alone were compared with those mea sured during the simultaneous application of bra dykinin and a kininase II inhibitor on the same pial artery. This procedure appears to be valid, since repetitive application of bradykinin showed the same vascular response. There was no sign of tachyphy laxis under our experimental conditions. The effect of potentiator C (10-5 M) on the con centration-response curve for bradykinin (10-8-10-5 M) on pial arteries is given in Fig. 4 . Potentiator C did not change significantly the concentration-re sponse curve for bradykinin. Figure 5 presents the effect of the more potent and specific kininase II inhibitor captopril on the response to bradykinin of pial arteries. The statis tical comparison of both curves revealed that the values of the reactions to bradykinin alone and to bradykinin together with captopril were not signif icantly different from each other. 
CHANGE OF VASCULAR DIAMETER (% OF CON TROll
Isolated guinea pig ileum
The potentiating effect of captopril (1.6 x 10-7 M) on the contraction-inducing action of brady kinin on the isolated guinea pig ileum is demon strated by the concentration-response curves shown in Fig. 6 . The statistical analysis of each group re vealed that between the values obtained in the pres ence and absence of captopril there exist significant (p < 0.01) differences at concentrations of 0.8 x 10-8, 1.6 X 10-8, and 3.2 x 10-8 M bradykinin. It is apparent that the efficacy of captopril does not depend on the mode of application (i.e., simulta neous or successive). Similarly, the bradykinin-in duced (0.8-3.2 x 10-8 M) reactions were signifi cantly (p < 0.01) increased in the presence of po tentiator C (1.6 x 10-6 M), to a degree that would correspond to a doubling of the bradykinin concen tration.
DISCUSSION
The data presented here demonstrate a dilating effect of bradykinin on feline middle cerebral ar teries in vitro and on pial arteries in situ. Further more, we have seen that bradykinin may in- 6'10-9 16"10-8 1. 6"10-7 1.6'10-6 1.6"10-9 1.6'10-8 1.6"10-7 1.6'10-6
BRADYKININ [M]
FIG. 6. Influence of captopril (1.6 x 10-7 M) on the brady kinin concentration-response curve of the isolated guinea pig ileum. Captopril was given simultaneously with (left; n = 12) or 2 min before (right; n = 10) bradykinin, after the brady kinin curve had been determined for the same ileum segment. Means ± SEM; n, number of segments tested. Solid line, bradykinin; broken line, bradykinin + 1.6 x 10-7 M captopril.
duce constriction of the isolated sublingual artery; this finding has been observed by other workers who studied different extracranial arteries in vitro (Toda, 1977) and in situ (Guth et aI., 1963) . How ever, bradykinin has also been reported to induce dilatations in arteries other than the cerebral ar teries (Toda, 1977; Cherry et aI., 1982) . This sug gests that bradykinin exerts variable responses on vascular smooth muscle, depending on species, muscle location, and experimental conditions. One possibility that might account for the dif ferent effects of bradykinin is the variable mode of its action. Some mechanisms will be mentioned here. Bradykinin may act directly on Bl or B2 receptors of vascular smooth muscle and thus induce con striction or dilatation (Regoli et aI., 1977; Regoli and Barabe, 1980) . Indirect effects of bradykinin, due to the release or inhibition of mediator substances, have also been reported: (a) release of dilating pros taglandins (Cherry et aI., 1982) , (b) release of an endothelium-derived relaxing factor (Cherry et aI., 1982) , and (c) release of histamine (Marceau et aI., 1981) . However, we did not test to see which of these mechanisms was responsible for the brady kinin effects reported here.
Our results obtained on cerebral arteries in vitro and in situ in the presence of kininase II inhibitors demonstrate that kininase II is not involved in the determination of the bradykinin effect under our ex perimental conditions. If kininase II was involved in the mechanism of action of bradykinin, a dis placement of the bradykinin concentration-re-sponse curve to the left (potentiation of the re sponse) should have been obtained in the presence of potentiator C or captopril. However, identical bra dykinin concentration-response curves were found during perivascular microapplication, with and without potentiator C or captopril in situ. Corre spondingly, captopril did not increase the brady kinin effect on middle cerebral artery in vitro, inde pendent of whether it was precontracted by PGF2c< or 5-HT. One could argue that the lack of brady kinin potentiation was due to the inability of the in hibitors to block the kininase II at this site. Such an assumption is unlikely, since captopril has been shown to block kininase II in isolated cerebral mi crovessels (Gimbrone et aI., 1979) and in cerebral parenchyma (Evered et aI., 1980) . The use of con centrations of inhibitors that were too low could also explain the lack of kininase II inhibition on cerebral arteries. The highest concentration of the more potent inhibitor used, captopril, was 10-5 M. Higher concentrations of captopril were not ap plied, since they induced slight dilatation themselves (Fig. 1) . In addition, it has been reported that 10-4 M and higher concentrations of captopril induce a diminution of the electrical membrane discharge and an inhibition of the mechanical force development of the isolated portal vein (Jandhyala et aI., 1980) . Therefore, we have tested whether the inhibitor concentrations on cerebral arteries tested are effec tive on the isolated guinea pig ileum, which is known to contain kininase II. These experiments were also run in parallel with the in situ studies to rule out a loss of biological activity of potentiator C and captopril during storage on an experimental day. The data demonstrate that a concentration of captopril, which was the same as that used on the cerebral arteries in vitro, and which was 1/100 of that used on pial arteries in situ, could significantly inhibit kininase II activity on the guinea pig ileum. This enhancement of the bradykinin-induced con traction of the ileum could be elicited to the same degree when captopril was given before or simul taneously with bradykinin. Consistent results were obtained with the weaker and less specific kininase II inhibitor, potentiator C.
Several enzymes with kininase-like activity have been reported for the brain (Yang and Neff, 1972; Poth et aI., 1975; Oliveira et aI., 1976; Arregui et aI., 1978; Camargo et aI., 1979; Gimbrone et aI., 1979; Wilk and Orlowski, 1979; Fuxe et aI., 1980; Walter et aI., 1980; Almenoff et aI., 1981; Kariya et aI., 1981) . These enzymes can be distinguished by several criteria, namely, their molecular weight, pH optimum, activation or inhibition by different ions or chelating agents, and (partially) cleavage at dif- ferent peptide bonds, as shown in Fig. 7 . Recently, it has been shown that the total cerebral kininase activity has a different regional distribution, and is 2-to II-fold higher than cerebral kininase II (Kariya et al., 1981) . The highest kininase II (or angiotensin converting enzyme) activity of the brain has been measured in neuronal or microsomal fractions of basal ganglia (Yang and Neff, 1972; Poth et al., 1975; Arregui et aI., 1978; Fuxe et aI., 1980; Kariya et aI., 1981) . Since both potentiator C and captopril ap pear to block only kininase II, one may conclude that other kininases may influence the effect of bra dykinin on the middle cerebral artery and the pial arteries of the parietal lobe. However, this does not exclude the possibility that kininase II modifies the vascular effect of bradykinin in other brain regions.
The mechanism of the reversal by captopril of the bradykinin effect on the sublingual artery remains unclear. One may speculate that a reduction of an giotensin II formation in the vessel wall or an at tenuation of a-adrenergic mechanisms, as sug gested by Kikta and Fregly (1982) , is responsible for this event. Additional experiments are neces sary to clarify the situation.
